SHELL ASSET MANAGEMENT CO - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 202 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
SHELL ASSET MANAGEMENT CO ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2020$49,000
-40.2%
1,9670.0%0.00%
-50.0%
Q3 2020$82,000
-12.8%
1,9670.0%0.00%0.0%
Q2 2020$94,000
-23.6%
1,967
+0.6%
0.00%
-33.3%
Q1 2020$123,000
-50.0%
1,956
-1.5%
0.00%
-40.0%
Q4 2019$246,000
+85.0%
1,985
-0.7%
0.01%
+66.7%
Q3 2019$133,000
-16.9%
1,999
-0.8%
0.00%
-25.0%
Q2 2019$160,000
-30.7%
2,016
-2.2%
0.00%
-20.0%
Q1 2019$231,0002,0620.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2020
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$14,787,0002.73%
DeepCurrents Investment Group LLC 416,800$9,620,0000.33%
DUALITY ADVISERS, LP 105,668$2,439,0000.21%
EULAV Asset Management 335,000$7,732,0000.21%
Virtus ETF Advisers LLC 19,375$447,0000.19%
Hennion & Walsh Asset Management, Inc. 135,214$3,121,0000.19%
PDT Partners, LLC 110,592$2,552,0000.18%
KETTLE HILL CAPITAL MANAGEMENT, LLC 70,256$1,622,0000.16%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$3,896,0000.12%
WOODWARD DIVERSIFIED CAPITAL, LLC 8,939$206,0000.12%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders